New bladder cancer treatment for patients who haven't responded to standard therapy

Plain-English translation of NCT06173349 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a new treatment called PLZ4-coated paclitaxel-loaded micelles (PPM) for bladder cancer that has returned or stopped responding to standard therapy. The medication is delivered directly into the bladder through a catheter once a week for 6 weeks. Researchers want to see if this treatment is safe and whether it helps shrink tumors.

Many patients with this type of bladder cancer either don't respond well to current standard treatments like BCG therapy or can't tolerate them. The next standard option—removing the entire bladder—is a major surgery that many patients want to avoid. This trial is exploring whether this new medication could be an effective option for people in this situation.

Do you qualify?

You likely qualify if…

you have been diagnosed with non-muscle invasive bladder cancer (early-stage bladder cancer that hasn't invaded the muscle layer)
your cancer has either come back after treatment or stopped responding to BCG therapy (a standard bladder cancer treatment)
you either refused or cannot tolerate having your bladder removed, which is normally recommended as the next step
you are at least 18 years old and in fairly good overall health
you have not had any other bladder cancer treatments (like chemotherapy or BCG) within the past 4 weeks
your blood counts, kidney function, and liver function are within acceptable ranges

You likely don't qualify if…

you are currently receiving or planning to receive other cancer treatments (chemotherapy, radiation, or immunotherapy) for your bladder cancer during the trial
you are unable or unwilling to use reliable birth control if you could become pregnant, or if you are pregnant or breastfeeding
you have severely low blood cell counts, kidney disease, or liver disease that would make treatment unsafe
you have serious lung problems or other medical conditions that would make participation unsafe

What participation looks like

You would come to the clinic once a week for 6 weeks to receive the medication, which is delivered directly into your bladder through a catheter over about 1 hour. During the trial, you'll have imaging scans (CT, MRI, or PET), bladder examinations with biopsies, and blood tests at various points. After the 6-week treatment period ends, you'll have follow-up visits at 3 weeks, 6 weeks, and then every 3 months for up to 2 years to check how you're doing.

AI-generated summary from trial data · Jun 13, 2026 · Not medical advice

Trial locations(1 site)

United States

University of California Davis Comprehensive Cancer Center, Sacramento, California